(untitled) - Falchi, L
Mosunetuzumab (mosun) Produces Durable Benefit in Patients (pts) with Newly Diagnosed Follicular Lymphoma (FL): Extended Follow up of the MITHIC-FL1 Trial. ICML 2025; Oral Session 027